Although the classic view of diabetic nephropathy (DN) has focused on events leading to glomerular dysfunction, the gradual decline of renal function in later stages of DN is invariably associated with tubulointerstitial fibrosis and tubular atrophy ([@B1]). Indeed, tubulointerstitial fibrosis and tubular atrophy appear to be better predictors of late-stage renal disease progression than glomerular pathology ([@B2]--[@B5]). For example, examination of nephrons from proteinuric diabetic patients shows that 71% of glomeruli display glomerulotubular junction abnormalities and 8--17% of glomeruli are atubular glomeruli ([@B6],[@B7]).

The mechanisms underlying tubular atrophy are incompletely delineated. Studies have shown that high glucose (HG) concentrations are associated with increased reactive oxygen species (ROS) production, which inhibits proximal tubular function and induces apoptosis ([@B8]--[@B10]). Apoptosis has been detected in renal proximal tubular cells (RPTCs) of diabetic mice ([@B11],[@B12]) and rats ([@B13],[@B14]) as well as in RPTCs of diabetic patients ([@B15]--[@B17]), suggesting that tubular apoptosis may precede tubular atrophy in atubular glomeruli. Although the link between ROS and tubular apoptosis seems clear, little is known about the genes involved in HG-induced RPTC apoptosis or ROS generation.

We previously reported that HG enhances angiotensinogen (*Agt*) gene expression via ROS generation in rat RPTCs in vitro ([@B18],[@B19]) and that in vivo overexpression of rat Agt in RPTCs induces hypertension, albuminuria, and RPTC apoptosis in diabetes ([@B20]). Conversely, we also reported that RPTC-selective overexpression of catalase (CAT) attenuates ROS generation, tubulointerstitial fibrosis, and tubular apoptosis as well as proapoptotic gene expression in diabetic mouse kidneys in vivo ([@B21],[@B22]). These data suggest that ROS generation may be directly or indirectly responsible for RPTC apoptosis in diabetes.

We now report that Bcl-2--modifying factor (Bmf), a proapoptotic gene that we identified via DNA chip microarray analysis, is differentially upregulated in RPTCs of *db*/*db* mice; we also validated this observation by immunohistochemistry and real-time quantitative PCR (qPCR). We further show enhanced Bmf expression in the RPTCs of mice with streptozotocin (STZ)-induced diabetes as well as in the kidneys of patients with diabetes. Finally, we found that Bmf overexpression enhances RPTC apoptosis and that HG in vitro induces Bmf mRNA expression via ROS generation and transforming growth factor-β1 (TGF-β1) expression.

RESEARCH DESIGN AND METHODS {#s2}
===========================

Chemicals and constructs. {#s3}
-------------------------

[d]{.smallcaps}-glucose, [d]{.smallcaps}-mannitol, diphenylene iodinium (DPI, an inhibitor of NADPH oxidase), rotenone (an inhibitor of mitochondrial electron transport chain complex I), apocynin (an inhibitor of NADPH oxidase), CAT, and monoclonal antibodies against β-actin were purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada). Normal glucose (5 mmol/L), Dulbecco's Modified Eagle's Medium (DMEM), 100× penicillin/streptomycin, FBS, and the expression vector pcDNA 3.1 were purchased from InVitrogen, Inc. (Burlington, ON, Canada). The caspase-3 activity assay kit was purchased from BD Biosciences Pharmingen (Mississauga, ON, Canada). Anti-Bmf and anti--c-Myc polyclonal antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Active human TGF-β1 was purchased from R&D Systems (Hornby, ON, Canada). Scrambled Silencer Negative Control \# 1 small interfering RNA (siRNA) and siRNAs for TGF-β1 and Bmf were procured from Qiagen, Inc. (Toronto, ON, Canada) and Ambion, Inc. (Austin, TX), respectively. Oligonucleotides were synthesized by InVitrogen, Inc. Restriction enzymes were purchased from InVitrogen, Inc. or Roche Biochemicals (Laval, QC, Canada).

CAT cDNA was a gift from Dr. Paul E. Epstein (University of Louisville, Louisville, KY). The plasmid pKAP2 containing the kidney-specific androgen-regulated protein (KAP) promoter responsive to testosterone stimulation was obtained from Dr. Curt Sigmund (University of Iowa, Iowa, IA) and has been described elsewhere ([@B23]).

Full-length rat Bmf cDNA was cloned from immortalized Wistar rat RPTCs ([@B24]) by conventional RT-PCR. Sense and antisense primers corresponding to nucleotides N+242 to N+265 (5′-ATG GAG CCA CCT CAG TGT GTG-3′) and N+799 to N+779 (5′-TCA CCA GGG ACC CAC CCC TTC-3′) of rat Bmf cDNA (NM_139258.1) were used in real-time PCR. Rat Bmf cDNA was subcloned into the pCMV-Myc mammalian expression vector containing the human cytomegalovirus promoter (CMV) (Clontech, Mountainview, CA), which fused an NH~2~-terminal c-Myc epitope.

Generation of *db*/*db* transgenic mice overexpressing rat CAT. {#s4}
---------------------------------------------------------------

Transgenic (Tg) mice (C57Bl/6 background) overexpressing rat CAT (rCAT) in RPTCs (line \#688) and homozygous *db*/*db* CAT-Tg mice were created in our laboratory (J.S.D.C.) and have been described previously ([@B21],[@B22]). The *db*/*db* and *db*/*db* CAT-Tg mice were used at age 20 weeks. Non-Tg, age- and sex-matched *db*/*m*+ littermates served as controls. The physiologic parameters of *db*/*m+*, *db*/*db*, and *db*/*db* CAT-Tg mice are displayed in [Supplementary Table III](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0141/-/DC1). All animals received standard mouse chow and water ad libitum. Animal care and all procedures were approved by the CHUM animal committee.

Mouse RPT isolation and DNA microarray analysis. {#s5}
------------------------------------------------

Animals were killed at age 20 weeks. The left and right kidneys were harvested immediately for immunohistochemistry and RPT isolation by Percoll gradient ([@B25]), respectively, as previously described ([@B26]).

Aliquots of freshly isolated mouse RPTs were immediately processed for total RNA isolation and gene chip microarray analysis. Briefly, total RNAs from three mice from each group were purified and reverse-transcribed into cDNA, which, in turn, served as the template for the generation of biotin-labeled cRNA (Enzo kit, Affymetrix, Inc., Santa Clara, CA), and then hybridized to Affymetrix Mouse Genome 430 2.0 microarray chips (Affymetrix, Inc.), according to the manufacturer's protocol. Affymetrix Mouse 430 A 2.0 chips contain ∼45,000 probe sets, corresponding to more than 39,000 mouse transcripts. The data were analyzed by computer with R statistical language (version 2.51). AffylmGUI (version 1.10.5) software and the LIMMA package (version 2.10.5) of the Bioconductor Library (release 2.0) were used for data analysis ([@B27]--[@B30]). The GCRMA (Gene Chip Robust Multi-array Average) algorithm was used for background correction of the data ([@B31]), and a linear model fit was undertaken on different contrasts representing the desired group comparisons (i.e., *db*/*db* vs. heterozygous *db*/*m*+ mice, *db*/*db* mice vs. *db*/*db* CAT-Tg mice). A list of normalized data (genes linked to the apoptotic pathway) from all probe sets represented on the chips was produced, and classification was performed by filtering based on *P* \< 0.05. The Gene Ontology database ([@B32]) for the different probe sets served to further select genes involved in the apoptosis process with *P* \< 0.01.

Real-time qPCR assays for gene expression. {#s6}
------------------------------------------

Total RNA was used in real-time qPCR to quantify the amount of Bmf mRNA expressed in mRPTs according to previously described methods ([@B20]). Forward (5′-CCCTTGGGGAGCAGCCCCCTG-3′) and reverse (5′-GCCGATGGAACTGGTCTGCAA-3′) primers of Bmf (NM_139258) and forward (5′-ATGCCATCCTGCGTCTGGACCTGGC-3′) and reverse (5′-AGCATTTGCGGTGCACGATGG-3′) primers of β-actin (NM_031144) were used.

Immunohistochemistry. {#s7}
---------------------

Immunohistochemical staining for Bmf was performed by standard avidin-biotin-peroxidase complex method (ABC Staining System, Santa Cruz Biotechnology, Inc.) as previously described ([@B20]--[@B22]).

Induction of diabetes. {#s8}
----------------------

Adult male mice (C57Bl/6 background) were rendered diabetic with STZ, as previously described ([@B20],[@B21]). Blood glucose was monitored twice weekly; mice were killed at 4 weeks after STZ administration. Both kidneys were removed, decapsulated, and weighed together. The physiologic parameters of nondiabetic and diabetic mice are displayed in [Supplementary Table IV](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0141/-/DC1). Left and right kidneys were processed for immunohistochemistry and RPT isolation, respectively ([@B20]--[@B22]).

Cell culture. {#s9}
-------------

Immortalized rat RPTCs at passages 13--18 were used in the current study using culture conditions reported previously ([@B18],[@B19]). Briefly, the cells were synchronized for 24 h in serum-free 5 mmol/L glucose DMEM at 80--90% confluence, preincubated in 5 mmol/L glucose DMEM containing 1% depleted FBS for 30 min, and then 20 mmol/L [d]{.smallcaps}-mannitol (for normalization of osmolality) or 20 mmol/L [d]{.smallcaps}(+)-glucose were added in the absence or presence of rotenone (1 × 10^−6^ mol/L), DPI (5 × 10^−6^ mol/L), apocynin (10^−5^ mol/L), or CAT (300 units/mL). The cells were then cultured for an additional 24 h, after which they were harvested and RNA was isolated for subsequent analysis for Bmf and β-actin mRNA quantification by real-time qPCR. To analyze ROS and hydrogen peroxide (H~2~O~2~) generation, cells were harvested and subjected to the lucigenin assay ([@B18],[@B19]) and H~2~O~2~ measurement kit (Hydrogen Peroxide Assay Kit, National Diagnostics, Atlanta, GA).

Transfections, apoptosis, and caspase-3 activity assays. {#s10}
--------------------------------------------------------

The pCMV-Myc mammalian expression vector containing N-terminally Myc-tagged rat Bmf **(**[Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0141/-/DC1)**)** was transiently transfected into RPTCs using Lipofectamine 2000 (InVitrogen). Cells were then incubated for 24 h in 5 mmol/L [d]{.smallcaps}-glucose plus 20 mmol/L [d]{.smallcaps}-mannitol (normal glucose) or 25 mmol/L [d]{.smallcaps}-glucose (HG) medium and then analyzed for apoptosis by transferase-mediated dUTP nick-end labeling (TUNEL) assay, followed by DAPI staining (TUNEL kit, Roche Diagnostics). The percentage of apoptotic RPTCs was estimated semiquantitatively. For each group, 8--9 fields (original magnification ×200) were randomly selected, and the captured TUNEL and DAPI images were overlayed using National Institutes of Health ImageJ (<http://rsb.info.nih.gov/ij/>) software. Cells labeled with both TUNEL and DAPI were noted as TUNEL-positive. The total number of TUNEL-positive cells was divided by the number of DAPI-stained cells and multiplied by 100 to derive the percentage of apoptotic cells per field. In some experiments, cells were harvested for caspase-3 activity assay and anti-Myc immunoblotting to confirm fusion gene expression. Caspase-3 activity was quantified fluorimetrically ([@B20]--[@B22]). Raw data were then normalized by cell lysate protein concentrations.

Coimmunoprecipitation of Myc-Bmf with Bcl-2 and Western blotting. {#s11}
-----------------------------------------------------------------

Coimmunoprecipitation (co-IP) of Myc-Bmf with Bcl-2 was performed according to previously described methods ([@B33]).

Bmf immunostaining of kidney biopsy samples of diabetic and nondiabetic patients. {#s12}
---------------------------------------------------------------------------------

Six kidney biopsy samples (paraffin sections) for immunostaining were obtained from the Department of Pathology of the CHUM. These studies were approved by the CHUM ethics committee, and all patients provided informed consent.

DNA gene chip analysis of human diabetic and nondiabetic kidneys. {#s13}
-----------------------------------------------------------------

Human renal biopsy samples were obtained from a multicenter study, the European Renal cDNA Bank-Kröner-Fresenius-Biopsy Bank (ERCB-KFB); all patients provided informed consent according to guidelines of each respective local ethics committee. DNA gene chip analysis was performed as previously described ([@B34]--[@B36]). Twenty-five individual biopsy samples, stratified by a reference pathologist at the ERCB, were analyzed, using 18 preimplantation kidney biopsy samples from healthy living donors as control samples and 7 samples for each region of the kidney (tubules, glomeruli, etc.) from 9 DN patients with type 2 diabetes mellitus (T2DM). Samples were processed as described, and microarrays from microdissected renal compartments were hybridized to an Affy 133plus chip ([@B34]--[@B36]). Image files were processed and normalized using the ExpressionFileCreator module in GenePattern pipeline (<http://genepattern.broadinstitute.org>). A custom CDF (Chip Description Files) annotation file from Brainarray (<http://brainarray.mbni.med.umich.edu>) was used to map the probes to the respective genes based on the updated genome annotation. The normalized log-transformed data were analyzed using the significance analysis of microarray method implemented in the TM4 suite (<http://www.tm4.org/mev/>) to detect the differentially regulated genes between the living donors and the DN samples with a false discovery rate of \<1%. The value "*q*" is a multiple testing corrected *P* value for false positives (briefly, the "*q*" value method first looks at the distribution of the *P* values, identifies at which value the *P* value becomes flattened, and then incorporates this information into the calculation of the adjusted *P* value).

Statistical analysis. {#s14}
---------------------

Unless otherwise noted, the data are expressed as means ± SEM. Statistical analysis was performed by the *t*test provided by GraphPad Prism 5.0 software (GraphPad, San Diego, CA; <http://www.graphpad.com/prism/Prism.htm>). Values of *P* ≤ 0.05 were considered statistically significant.

RESULTS {#s15}
=======

Microarray analysis. {#s16}
--------------------

Normalized data of the different probe sets by setting *P* \< 0.05 on the chips generated a list of 21 upregulated and 25 downregulated genes associated with apoptosis in RPTs of *db*/*db* mice compared with heterozygous *db*/*m*+ or *db*/*db* CAT-Tg mice ([Supplementary Tables I and II](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0141/-/DC1)). Our raw and normalized data are available in the public domain Gene Expression Omnibus National Center for Biotechnology Information database (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19640>).

The Gene Ontology database was used to screen for probe sets involved in apoptotic processes. Classification was further filtered by setting *P* \< 0.01, compiling a list of five upregulated ([Table 1](#T1){ref-type="table"}) and six downregulated proapoptotic genes ([Table 2](#T2){ref-type="table"}) in *db*/*db* mice, compared with *db*/*m*+ and *db*/*db* CAT-Tg mice. We chose Bmf in the current study because its expression is at least threefold higher in RPTCs of *db*/*db* mice compared with *db*/*m*+ and *db*/*db* CAT-Tg mice.

###### 

Proapoptotic genes upregulated in microarray chips of *db*/*db* vs. *db*/*m*+ and *db*/*db* vs. *db*/*db*CAT-Tg mice overexpressing CAT \*

![](474tbl1)

###### 

Proapoptotic genes downreguated in microarray chips of *db*/*db* vs. *db*/*m*+ and *db*/*db* vs. *db*/*db*CAT-Tg mice overexpressing CAT \*

![](474tbl2)

Validation of Bmf mRNA expression in mouse RPTs by real-time PCR. {#s17}
-----------------------------------------------------------------

To validate the results obtained by DNA microarray, real-time qPCR was performed using primers specific for mouse Bmf mRNA. [Figure 1*A*](#F1){ref-type="fig"} displays the results of Bmf mRNA expression in freshly isolated RPTs from *db*/*m*+, *db*/*db*, and *db*/*db* CAT-Tg mice. The baseline expression of Bmf mRNA in *db*/*db* mice was sixfold higher than in *db*/*m*+ mice (*P* \< 0.005). This increase was significantly attenuated in *db*/*db* CAT-Tg mice (*P* \< 0.05).

![Bmf expression is elevated in RPTs of *db*/*db* diabetic mice. *A*: Real-time qPCR for Bmf mRNA levels in freshly isolated RPTs from *db*/*m*, *db*/*db*, and *db*/*db*CAT-Tg mice. Values were corrected to β-actin. *B*: Bmf immunohistochemical (IHC) staining in kidney sections (original magnification ×600) from (*a*) *db*/*m*^+^, (*b*) *db*/*db*, and (*c*) *db*/*db*CAT-Tg mice; (*d*) presents a nonimmune rabbit serum control. G, Glomerulus. *C*: Quantification of Bmf IHC staining. Values are the mean ± SEM, *n* = 5--7 for each group. \**P* \< 0.05; \*\*\**P* \< 0.005. N.S., not significant. (A high-quality color representation of this figure is available in the online issue.)](474fig1){#F1}

Validation of Bmf expression by immunohistochemistry. {#s18}
-----------------------------------------------------

We previously reported TUNEL staining on kidney sections of *db*/*m*+, *db*/*m*+ CAT-Tg, *db*/*db*, and *db*/*db*CAT-Tg mice and showed that apoptotic cells were found in RPTCs of *db*/*db* mice but not in *db*/*m*+, *db*/*m*+ CAT, and *db*/*db*CAT-Tgs ([@B22]). To validate whether Bmf expression was increased in RPTCs of 20-week-old T2DM *db*/*db* mice, immunohistochemical analysis was performed using an anti-Bmf antibody. Increased immunostaining for Bmf was observed in the RPTCs of diabetic *db*/*db* mice ([Fig. 1*B*](#F1){ref-type="fig"}, *b*) compared with the RPTCs of nondiabetic *db*/*m*^+^ control mice ([Fig. 1*B*](#F1){ref-type="fig"}, *a*). CAT overexpression effectively attenuated Bmf expression, as observed in RPTs of *db*/*db* CAT-Tg mice ([Fig. 1*B*](#F1){ref-type="fig"}, *c*). No immunostaining was observed with nonimmune control serum in *db*/*db* mice ([Fig. 1*B*](#F1){ref-type="fig"}, *d*). Quantification of Bmf immunostaining confirmed enhanced Bmf expression in RPTCs of *db*/*db* mice ([Fig. 1*C*](#F1){ref-type="fig"}). Similarly, kidneys from adult mice with STZ-induced diabetes also exhibited enhanced Bmf immunostaining in RPTCs ([Fig. 2*A*](#F2){ref-type="fig"}, *b* and *B*) compared with nondiabetic littermates ([Fig. 2*A*](#F2){ref-type="fig"}, *a* and *B*). Treatment of diabetic mice with insulin reduced Bmf expression to control levels ([Fig. 2*A*](#F2){ref-type="fig"}, *c* and *B*). No immunostaining was observed in sections treated with nonimmune control serum ([Fig. 2*A*](#F2){ref-type="fig"}, *d*). These results were further validated by performing real-time qPCR for Bmf using RNA isolated from RPTCs of STZ-induced diabetic mice. [Figure 2*C*](#F2){ref-type="fig"} shows a significant increase (*P* \< 0.05) in Bmf mRNA expression levels in STZ-induced diabetic mice compared with control and insulin-treated STZ-injected mice.

![Bmf expression is upregulated in RPTs from STZ-induced diabetic mouse kidneys. *A*: Bmf immunohistochemical (IHC) staining in kidney sections (original magnification ×600) from nondiabetic control (*a*), STZ-induced diabetic (*b*), and insulin-treated STZ-injected mice (*c*); nonimmune rabbit serum control is also presented (*d*). *B*: Quantification of Bmf-IHC. Values are the mean ± SEM, *n* = 4--12. *C*: Real-time qPCR for Bmf mRNA levels in freshly isolated RPTs from control and STZ-induced diabetic and insulin-treated STZ-injected mice. Values were corrected to β-actin. \**P* \< 0.05; \*\**P* \< 0.01. N.S., not significant. (A high-quality color representation of this figure is available in the online issue.)](474fig2){#F2}

HG induces ROS generation and Bmf mRNA expression in RPTCs in vitro. {#s19}
--------------------------------------------------------------------

Immortalized rat RPTCs were cultured in normal glucose or HG medium with or without rotenone, CAT, DPI, or apocynin. Cells were then harvested to assess ROS generation with the lucigenin assay, and RNA was isolated for real-time qPCR analysis. RPTCs cultured in HG produced significantly higher amounts of ROS than RPTCs cultured in normal glucose ([Fig. 3*A*](#F3){ref-type="fig"}), and these increases could be markedly attenuated or inhibited by rotenone, CAT, DPI, or apocynin. Furthermore, RPTCs cultured in HG medium exhibited fourfold higher Bmf mRNA expression than RPTCs cultured in normal glucose medium (*P* ≤ 0.01; [Fig. 3*B*](#F3){ref-type="fig"}). The HG-stimulated increases in Bmf mRNA expression were inhibited by rotenone, CAT, DPI, and apocynin.

![HG stimulates ROS generation and Bmf mRNA expression in rat RPTCs in vitro. *A*: ROS generation of RPTCs cultured in normal glucose (5 mmol/L [d]{.smallcaps}-glucose plus 20 mmol/L [d]{.smallcaps}-mannitol) and HG (25 mmol/L [d]{.smallcaps}-glucose) media with various inhibitors, as indicated. Values are corrected to lysate protein levels. *B*: Real-time qPCR for Bmf mRNA levels in RPTCs in vitro after treatment with normal glucose or HG and various inhibitors, as indicated. *C*: Real-time qPCR for Bmf mRNA levels in RPTCs in response to active human TGF-β1. *D*: Real-time qPCR for Bmf mRNA levels in RPTCs in vitro after transfection with siRNA of TGF-β1 or scrambled siRNA in normal glucose (□) and HG (■) media. Values are corrected to β-actin levels. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.005; N.S., not significant.](474fig3){#F3}

TGF-β1 upregulates Bmf mRNA expression in rat RPTCs. {#s20}
----------------------------------------------------

To investigate the mechanism(s) of HG-stimulation of Bmf expression, RPTCs were cultured with active human TGF-β1 in normal glucose medium. TGF-β1 increased Bmf mRNA expression in a concentration-dependent manner ([Fig. 3*C*](#F3){ref-type="fig"}). Conversely, knockdown of TGF-β1 with siRNA attenuated HG-stimulation of Bmf mRNA expression in RPTCs ([Fig. 3*D*](#F3){ref-type="fig"}).

Cloning and amino acid sequence of rat Bmf. {#s21}
-------------------------------------------

We cloned Bmf cDNA from rat RPTCs (Wistar strain) by conventional RT-PCR. Rat and mouse Bmf consists of 185 amino acids and is 98.9% homologous. Rat Bmf cDNA was then subcloned into the pCMV-Myc mammalian expression vector, which fused an NH~2~-terminal c-Myc epitope tag ([Supplementary Fig. 1*A* and *B*)](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0141/-/DC1).

Bmf overexpression leads to activation of caspase-3 and RPTC apoptosis. {#s22}
-----------------------------------------------------------------------

To study the role of Bmf in apoptosis, rat RPTCs were transiently transfected with NH~2~-terminally Myc-tagged Bmf or an empty vector, and caspase-3 activity was determined in cell lysates. Expression of the fusion protein was confirmed by RT-PCR ([Fig. 4*A*](#F4){ref-type="fig"}) and anti-Myc immunoblotting ([Fig. 4*B*](#F4){ref-type="fig"}). Caspase-3 activity was significantly increased in lysates from cells transiently transfected with the Bmf fusion protein compared with lysates from cells transiently transfected with empty vector (*P* \< 0.005). Caspase-3 activity was further augmented when RPTCs were cultured in HG medium (*P* \< 0.005; [Fig. 4*C*](#F4){ref-type="fig"}). Knockdown of Bmf with siRNA reduced HG-induced apotposis (TUNEL assay) in RPTCs compared with scrambled siRNA ([Fig. 4*D*](#F4){ref-type="fig"}).

![Overexpression of rat Bmf induces caspase-3 activity in rat RPTCs in vitro. *A*: RPTCs were transiently transfected by lipofectamine 2000 with the empty vector, pCMV-Myc or plasmid containing NH~2~-terminally tagged rat Bmf cDNA (pCMV-Myc rat Bmf). Expression of the Myc-rat Bmf mRNA was confirmed by conventional RT-PCR and quantified by densitometry. *B*: Anti-Myc immunoblotting was also performed. The nonspecific band serves as loading control. *C*: Caspase 3 activity in RPTCs transfected with empty vector (pCMV-Myc) or pCMV-Myc rat Bmf in normal glucose (□) and HG (■) media. Values are corrected to lysate protein levels. Values are the mean ± SEM, *n* = 4--8. \*\*\**P* \< 0.005. UV, ultraviolet. *D*: TUNEL images (*a--d*) and quantification of apoptotic cells (*E*) in vitro. After transfection with scrambled siRNA (*a* and *c*) or Bmf siRNA (*b* and *d*) in RPTCs cultured in normal glucose (NG, *a* and *b*) or HG (*c* and *d*) medium, cells were fixed and subjected to TUNEL (green) and DAPI (blue) staining (original magnification ×200). White arrows indicate TUNEL-positive cells; (*e*) quantification of TUNEL-positive cells (*n* = 3 experiments). \*\**P* \< 0.01; N.S., not significant. (A high-quality color representation of this figure is available in the online issue.)](474fig4){#F4}

RPTCs transiently transfected with NH~2~-terminally Myc-tagged Bmf exhibited fourfold increase in TUNEL-positive cells compared with empty vector-transfected cells (*P* \< 0.005; [Fig. 5*A*](#F5){ref-type="fig"}, and *B*). Parallel assays with lysates from transfected cells confirmed the expression of Myc-tagged Bmf ([Fig. 5*C*](#F5){ref-type="fig"}).

![Overexpression of rat Bmf increases TUNEL-positive cells and coimmunoprecipitates (Co-IP) with Bcl-2 in rat RPTCs in vitro. *A*: RPTCs were transiently transfected with the empty vector, pCMV-Myc, or pCMV-Myc rat Bmf. Cells were incubated for 24 h in 25 mmol/L [d]{.smallcaps}-glucose, then fixed and subjected to TUNEL and DAPI staining. TUNEL (green) and DAPI (blue) staining (original magnification ×200) are shown for RPTCs transfected with empty vector and pCMV-Myc rat Bmf. DNase-treated cells serve as TUNEL-positive controls. Cells left untreated with terminal transferase serve as a TUNEL-negative control. *B*: Quantification of TUNEL-positive cells per field is shown. Values are presented as percentages of TUNEL-positive cells/total cells per field ± SEM (*n* = 8 or 9). \*\*\**P* \< 0.005. *C*: Expression of the Myc-rat Bmf fusion protein was confirmed by anti-Myc immunoblotting, with β-actin as the loading control. *D*: Interaction of Myc-Bmf with Bcl-2 in rat RPTCs: (*a*) Immunoblotting for Bcl-2 in cytosolic fractions of rat RPTCs before (total lysate, TL) and after Co-IP with anti-Myc; (*b*) immunoblotting for Myc in cytosolic fractions of rat RPTCs on the same membrane after immunobotting for anti-Bcl-2 in panel *a*. The relative density of Bcl-2 or Myc in RPTCs cultured normal glucose (5 mmol/L [d]{.smallcaps}-glucose plus 20 mmol/L [d]{.smallcaps}-mannitol DMEM) was expressed as controls (100 arbitrary units). Rabbit purified IgG (3 μg) was used as the control for Co-IP experiments. Values are the mean ± SEM for 4 independent experiments. \*\*\**P* \< 0.005; N.S., not significant. □, normal glucose; ■, high glucose medium. (A high-quality digital representation of this figure is available in the online issue.)](474fig5){#F5}

Bmf interacts with Bcl-2 in rat IRPTCs. {#s23}
---------------------------------------

To investigate Bmf interaction with Bcl-2, coimmunoprecipitation experiments of Myc-Bmf with Bcl-2 were performed. Significant increases in coimmunoprecipitated Bcl-2 ([Fig. 5*D*](#F5){ref-type="fig"}, *a*) but not Myc-Bmf ([Fig. 5*D*](#F5){ref-type="fig"}, *b*) were observed in rat IRPTCs overexpressing Myc-Bmf cultured in HG medium.

Bmf expression in diabetic human kidneys. {#s24}
-----------------------------------------

The clinical characteristics of the patients are shown in [Supplementary Table VI](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0141/-/DC1). All had kidney cancer, which was the reason for the nephrectomies; some had T2DM, but others did not. Immunohistochemistry revealed Bmf expression in the renal distal tubules but not in the renal proximal tubules (RPTs) of the normal portions of human nephrectomy specimens from nondiabetic patients with kidney cancer ([Fig. 6*A*](#F6){ref-type="fig"}, *a*--*c*). However, increased immunostaining for Bmf was observed in RPTs of the normal portions of nephrectomy specimens from patients with kidney cancer who also had diabetes ([Fig. 6*A*](#F6){ref-type="fig"}, *d*--*f*). Interestingly, double immunostaining revealed frequent colocalization of Bmf overexpression in TUNEL-positive apoptotic RPTCs in diabetic kidney but not in nondiabetic kidney ([Fig. 6*B*](#F6){ref-type="fig"}).

![Enhanced Bmf expression in RPTs from human kidneys from patients with diabetes. *A*: Bmf immunohistochemical staining in human kidney sections (original magnification ×200) from three nondiabetic cancer patients (*a*, patient with papillary variant carcinoma; *b*, patient with clear cell carcinoma; and *c*, patient with thyroid-like renal carcinoma) and three diabetic cancer patients (*d*, patient with papillary variant carcinoma and evidence of DN \[nodular with tubular atrophy and interstitial fibrosis\]; *e*, patient with clear cell carcinoma and no evidence of DN; and *f*, patient with clear cell carcinoma and nephroangiosclerosis with evidence of DN \[secondary focal glomerulosclerosis, tubular atrophy, and interstitial fibrosis\]). DT, distal tubule; G, glomerulus. *B*: Colocalization of Bmf expression and TUNEL-positive cells in human kidneys. Nondiabetic human kidney (patient I.D. \#C,) and diabetic human kidney with DN (patient I.D. \#D) were sectioned, subjected to TUNEL assay to visualize apoptotic cells (green), and then incubated with anti-Bmf antibody, followed by anti-goat AlexaFluor 594 to demonstrate Bmf expression (red). Cells staining positively for TUNEL and Bmf appear yellow (merged image). Original magnification ×200. Arrows indicate cells that stained positively for TUNEL and Bmf. G, glomerulus; DT, distal tubule. (A high-quality color representation of this figure is available in the online issue.)](474fig6){#F6}

DNA gene chip microarray analysis (Affymetrix GeneChip HGU 133plus 2 chip) of microdissected nephrons from seven patients with T2DM revealed modestly but significantly enhanced Bmf expression in glomeruli (1.48-fold increase) and tubulointerstitium (1.39-fold increase) compared with 18 control biopsy specimens from kidneys from living donors taken at the time of transplant (*q* \< 0.01, where *q* value is a multiple-testing corrected *P* value). [Supplementary Table VII](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0141/-/DC1) summarizes the clinical characteristics of the patients in the gene microarray analysis.

DISCUSSION {#s25}
==========

The current study documents enhanced Bmf expression in RPTCs of *db*/*db* mice, STZ-induced diabetic mice, and kidneys from patients with T2DM and shows that Bmf overexpression enhances RPTC apoptosis, indicating a potential role for Bmf in mediating tubular atrophy in the diabetic kidney.

To identify the proapoptotic genes regulated by ROS in *db*/*db* mice RPTCs, we used gene chip microarrays as an initial screen ([@B37]). A combination of high *P* values, fold changes, and Gene Ontology annotation ([@B32]) allowed us to obtain an overview of the genetic regulation of RPTC apoptosis occurring in murine models of T2DM.

We identified Bmf as one of five putative proapoptotic genes that were differentially upregulated (*P* \< 0.01 and \>1.5-fold increase) in RPTs of *db*/*db* mice compared with *db*/*m*+ and *db*/*db* CAT-Tg mice. The upregulation of Bmf mRNA and protein expression in RPTCs of *db*/*db* mice was confirmed by real-time qPCR and immunostaining.

To confirm enhanced Bmf expression, we used another model of diabetes, STZ-induced diabetes in mice ([@B20]). Our results document significant upregulation of Bmf expression in RPTCs of STZ-induced diabetes and its reversal by insulin.

There is evidence that HG induces apoptosis in RPTCs via ROS generation ([@B20],[@B38]). Our present data show that HG also stimulates Bmf mRNA expression, which can be inhibited by rotenone, CAT, DPI, and apocynin. Cellular H~2~O~2~ and mitochondrial ROS levels were also significantly higher in RPTCs incubated in HG medium than in RPTCs cultured in normal glucose and were normalized in the presence of CAT ([Supplementary Fig 2*a* and *b*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0141/-/DC1)). These observations indicate that ROS derived from mitochondrial oxidative metabolism may mediate, at least in part, HG-induced Bmf expression, which in turn would promote RPTC apoptosis.

To provide evidence that Bmf can directly induce RPTC apoptosis, we overexpressed Bmf in rat RPTCs. Transient transfection of RPTCs with rat Bmf cDNA resulted in activation of caspase-3 parallel with increases in the number of apoptotic cells, similar to that observed in transfected fibroblasts and cancer cells ([@B39]). We were unable to detect increases in endogenous rat Bmf expression in RPTCs by immunoblotting or immunofluorescence (data not shown) using the same anti-Bmf antibodies used for immunohistochemistry. Of note, Schmelzle et al. ([@B40]) also observed that commercially available anti-Bmf antibodies do not work in immunoblotting versus immunohistochemistry of Bmf.

The precise mechanism(s) by which HG evokes Bmf expression in RPTC apoptosis remains unclear. Our present data show that TGF-β1 stimulates Bmf mRNA expression and that knockdown of TGF-β1 with siRNA attenuates Bmf mRNA expression in RPTCs in HG. These observations are consistent with findings of Ramjaun et al. ([@B41]) showing that TGF-β1 stimulates *Bmf* gene expression. ROS could induce phosphorylation of Bmf via c-Jun NH~2~-terminal kinase ([@B42]) or other signaling pathways. Phosphorylated Bmf would then translocate from the cytoskeleton to bind antiapoptotic proteins (i.e., Bcl-2 and Bcl-xL), which are located on the mitochondria, to interfere with Bcl-2/Bcl-xL mitochondrial gatekeeping and thus allow enhanced Bax binding to the mitochondrion. This would result in the collapse of the mitochondrial transmembrane potential and thus activation of the intrinsic pathway of apoptosis. Our findings that Myc-Bmf coimmunoprecipitates Bcl-2 in rat RPTCs lend further support to this notion.

We searched the publicly accessible National Center for Biotechnology Information data bank (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1009>) for microarray studies performed on biopsy specimens from patients with DN ([Supplementary Table V](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0141/-/DC1)) to confirm our findings in *db*/*db* mice. Bmf was not detectable, however, in human kidneys from patients with diabetes when the first generation of chips (Affymetrix Human Genome U95 Version 2 Array) was used because a Bmf probeset was not present in these chips. Bmf expression was upregulated, however, in kidney allografts from living donors compared with at implantation before revascularization (0 months) using the Affymetrix Human Genome U133 Plus 2.0 Array (Affy 133plus chip), which contains the Bmf probeset. These findings indicate that Bmf expression may be upregulated in human kidneys under pathologic conditions, including DN.

Indeed, this possibility is supported by our immunohistochemistry studies that show increased Bmf expression in RPTs taken from nonmalignant portions of kidneys removed removed from diabetic patients due to kidney cancer compared with those taken from nondiabetic patients with kidney cancer. Interestingly, RPTCs overexpressing Bmf frequently stained positive for TUNEL in diabetic human kidney. Furthermore, the Affy 133plus chip assay revealed significantly upregulated Bmf expression (*q* \< 0.01, where *q* value is a multiple testing corrected *P* value) in microdissected glomeruli (1.48-fold increase) and tubulointerstitium (1.39-fold increase) from patients with T2DM compared with nondiabetic patients (kidney donors). The 1.39-fold versus 3-fold increases in Bmf expression in human diabetic tubulointerstitium and *db*/*db* mice RPTs, respectively, are difficult to reconcile. It is possible that Bmf mRNA expression in human tubulointestitium might have been underestimated because of the use of a mixture of tubules and interstitium versus the \>90% purity of our *db*/*db* mouse RPT fraction. Additional qPCR studies are needed to compare Bmf expression in human RPTs with or without T2DM.

Our results may have clinical implications for patients with T2DM. Because tubular apoptosis is one of the characteristic morphologic changes in human diabetic kidneys ([@B15]--[@B17]) and tubular atrophy appears to be a better indicator of disease progression than glomerular pathology ([@B2]--[@B4]), we suggest that RPTC apoptosis may be an initial mechanism for tubular atrophy in T2DM. Our present data point toward Bmf as one of the mediators of this process. However, whether enhanced Bmf expression directly or indirectly induces RPTC apoptosis in human T2DM remains to be investigated.

In summary, the current study suggests an important role for Bmf in mediating RPTC apoptosis in the diabetic mouse kidney in vivo, and, likely, in diabetic human kidneys. Our observations raise the possibility that selective targeting of this proapoptotic protein may provide a novel approach in preventing or reversing the pathologic manifestations of DN, particularly tubular atrophy.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0141/-/DC1>.
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